| Ironwood Pharmaceuticals aims to create, develop, and commercialize differentiated medicines that provide clear and meaningful therapeutic benefits to patients suffering from chronic diseases. We are committed to continually evaluating the emerging product profile and market potential of each drug candidate throughout the development process, enabling us to focus our efforts on the most promising candidates.
Linaclotide, our GC-C agonist, is an investigational drug for the treatment of irritable bowel syndrome with constipation and chronic constipation. We have ongoing efforts to identify and develop additional product candidates, including potential treatments for upper gastrointestinal disease, pain and inflammation, respiratory disease, and cardiovascular disease. In addition, Ironwood is actively engaged in evaluating externally discovered drug candidates at all stages of development.
|
